Amgen Inc. (0R0T.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
204.71+28.24 (+16.00%)
At close: 5:14PM BST
| Previous close | 176.47 |
| Open | 201.26 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 201.26 - 204.73 |
| 52-week range | 201.26 - 204.73 |
| Volume | 316 |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | 20.76 |
| EPS (TTM) | 9.86 |
| Earnings date | 02 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Boasting A 70% Return On Equity, Is Amgen Inc. (NASDAQ:AMGN) A Top Quality Stock?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- Simply Wall St.
Four Days Left To Buy Amgen Inc. (NASDAQ:AMGN) Before The Ex-Dividend Date
Amgen Inc. ( NASDAQ:AMGN ) stock is about to trade ex-dividend in four days. The ex-dividend date occurs one day before...
- Bloomberg
Amgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO
(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is considering fundraising options including an initial public offering, according to people familiar with the matter.The company is interviewing investment banks as it weighs alternatives, which also include a private funding round, the people said, asking not to be identified because the matter is private.Hummingbird could seek to raise about $200 million to $300 million in a share sale, which could take pl
© 2021 Verizon Media. All rights reserved.
